Literature DB >> 8873393

Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine.

C S McLean1, D Ni Challanáin, I Duncan, M E Boursnell, R Jennings, S C Inglis.   

Abstract

The vaccine potential of a genetically disabled Herpes Simplex Virus Type 1 virus (DISC HSV-1) was investigated in the guinea pig model of intravaginal (i.vag.) HSV-2 infection. Three mucosal vaccination routes, i.vag., intranasal (i.n.) and oral, were compared for their ability to protect guinea pigs from challenge with wild-type HSV-2. Each was effective, particularly the i.n. route, which almost completely abolished primary disease. This was accompanied by significantly lower challenge virus titres in vaginal swabs collected from the vaccinated animals. In all cases, vaccination with the inactivated virus preparation provided substantially less protection from disease than the live DISC HSV-1 by the equivalent route. Antibody levels in serum and vaginal washes were measured both after vaccination and challenge by ELISA and neutralization tests. The highest titres were observed following administration of the DISC HSV-1 vaccine by the i.n. route. Significant increases in IgA and IgG in vaginal wash fluids were also found in these vaccinated animals.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8873393     DOI: 10.1016/0264-410x(95)00259-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2.

Authors:  X Da Costa; M F Kramer; J Zhu; M A Brockman; D M Knipe
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity.

Authors:  Mark A Brockman; David M Knipe
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  HSV Recombinant Vectors for Gene Therapy.

Authors:  Roberto Manservigi; Rafaela Argnani; Peggy Marconi
Journal:  Open Virol J       Date:  2010-06-18

4.  Evaluation of a novel, anti-herpes simplex virus compound, acyclovir elaidate (P-4010), in the female guinea pig model of genital herpes.

Authors:  R Jennings; T L Smith; F Myhren; J Phillips; M L Sandvold
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

5.  Optimal long-term humoral responses to replication-defective herpes simplex virus require CD21/CD35 complement receptor expression on stromal cells.

Authors:  Mark A Brockman; Admar Verschoor; Jia Zhu; Michael C Carroll; David M Knipe
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 6.  HSV-2: in pursuit of a vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

Review 7.  Vaccines against genital herpes: progress and limitations.

Authors:  Lynda A Morrison
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 8.  Recent progress in herpes simplex virus immunobiology and vaccine research.

Authors:  David M Koelle; Lawrence Corey
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

Review 9.  Herpes keratitis.

Authors:  A M Rowe; A J St Leger; S Jeon; D K Dhaliwal; J E Knickelbein; R L Hendricks
Journal:  Prog Retin Eye Res       Date:  2012-08-27       Impact factor: 21.198

Review 10.  Prospects and perspectives for development of a vaccine against herpes simplex virus infections.

Authors:  Shane C McAllister; Mark R Schleiss
Journal:  Expert Rev Vaccines       Date:  2014-07-31       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.